Print Page  Close Window


SEC Filings

S-1/A
OREXIGEN THERAPEUTICS, INC. filed this Form S-1/A on 02/16/2007
Entire Document
 
Table of Contents

 
OREXIGEN THERAPEUTICS, INC.
(a development stage company)

BALANCE SHEETS
 
                         
                Pro Forma
 
                Stockholders’
 
                Equity at December 31,
 
    December 31,     2006
 
    2005     2006     (Note 2)  
                (Unaudited)  
 
                         
ASSETS
Current assets:
                       
Cash and cash equivalents
  $ 8,739,925     $ 19,425,433          
Investment securities, available-for-sale
    18,907,187       14,988,170          
Prepaid expenses and other current assets
    264,823       222,317          
                         
Total current assets
    27,911,935       34,635,920          
Property and equipment, net
    145,400       528,077          
Restricted cash
    30,000       155,000          
Other assets
    26,294       1,490,987          
                         
Total assets
  $ 28,113,629     $ 36,809,984          
                         
 
LIABILITIES AND STOCKHOLDERS’ EQUITY (DEFICIT)
Current liabilities:
                       
Accounts payable
  $ 1,275,265     $ 1,698,666          
Accrued expenses
    136,747       3,203,725          
Deferred revenue, current portion
    88,235       88,235          
                         
Total current liabilities
    1,500,247       4,990,626          
Deferred revenue, less current portion
    1,323,530       1,235,294          
Long-term liabilities
          534,052          
Commitments and contingencies
                       
Series A and B redeemable convertible preferred stock, $.001 par value, 24,152,544 shares authorized, issued and outstanding at December 31, 2005 and 2006; aggregate liquidation preference of $46,000,000 at December 31, 2005 and 2006; no shares issued and outstanding pro forma (unaudited)
    45,866,396       45,896,934     $  
Stockholders’ equity (deficit):
                       
Common stock, $.001 par value, 35,000,000 shares authorized at December 31, 2005, 50,000,000 shares authorized at December 31, 2006; 4,706,084 and 4,796,084 shares issued and outstanding at December 31, 2005 and 2006, respectively; 37,720,558 shares issued and outstanding, pro forma (unaudited)
    4,706       4,796       37,721  
Series C convertible preferred stock, $.001 par value, no shares authorized, issued or outstanding at December 31, 2005 and 8,771,930 shares authorized, issued and outstanding at December 31, 2006; no shares issued and outstanding, pro forma (unaudited)
          8,772        
Additional paid-in capital
    5,046,673       33,296,081       79,168,862  
Deferred compensation
    (3,916,283 )            
Accumulated other comprehensive income (loss)
    (47,348 )     11,433       11,433  
Deficit accumulated during the development stage
    (21,664,292 )     (49,168,004 )     (49,168,004 )
                         
Total stockholders’ equity (deficit)
    (20,576,544 )     (15,846,922 )   $ 30,050,012  
                         
Total liabilities and stockholders’ equity (deficit)
  $ 28,113,629     $ 36,809,984          
                         
 
See accompanying notes.


F-3